Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 16/20 | 0.77 |
| ▸ | HTR1A | P08908 | 15/20 | 0.77 |
| ▸ | HTR2A | P28223 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.64 |
| ▸ | HTR6 | P50406 | 5/20 | 0.64 |
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9527241 | 0.88 | OPRM1 (0.78) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL7536094 | 0.88 | OPRM1 (0.78) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL7535919 | 0.87 | OPRM1 (0.76) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL7543848 | 0.87 | HTR1A (1.00) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL7859795 | 0.85 | OPRM1 (0.74) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL4194997 | 0.85 | HTR1A (1.00) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL11327571 | 0.85 | OPRM1 (0.73) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL11320856 | 0.85 | OPRM1 (0.73) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| SCHEMBL7649906 | 0.84 | HTR1A (0.83) | OPRM1OPRK1DRD2HTR1AHTR2A | |
| SCHEMBL1122147 | 0.83 | OPRM1 (0.71) | OPRM1OPRK1DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRK1 5/4885DRD2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.